Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036572 (
seizures
)
80,221
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Initially identified in high-grade gliomas, mutations in the
PTEN
tumor-suppressor are also found in many sporadic cancers and a few related autosomal dominant hamartoma syndromes.
PTEN
is a 3'-specific phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3) phosphatase and functions as a negative regulator of PI3K signaling. We generated a tissue-specific deletion of the mouse homolog Pten to address its role in brain function. Mice homozygous for this deletion (PtenloxP/loxP;Gfap-cre), developed
seizures
and ataxia by 9 wk and died by 29 wk. Histological analysis showed brain enlargement in PtenloxP/loxP;Gfap-cre mice as a consequence of primary granule-cell dysplasia in the cerebellum and dentate gyrus. Pten mutant cells showed a cell-autonomous increase in soma size and elevated phosphorylation of Akt. These data represent the first evidence for the role of Pten and Akt in cell size regulation in mammals and provide an animal model for a human phakomatosis condition, Lhermitte-Duclos disease (LDD).
...
PMID:Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. 1172 26
Somatic inactivation of
PTEN
occurs in different human tumors including glioblastoma, endometrial carcinoma and prostate carcinoma. Germline mutations in
PTEN
result in a range of phenotypic abnormalities that occur with variable penetrance, including neurological features such as macrocephaly,
seizures
, ataxia and Lhermitte-Duclos disease (also described as dysplastic gangliocytoma of the cerebellum). Homozygous deletion of Pten causes embryonic lethality in mice. To investigate function in the brain, we used Cre-loxP technology to selectively inactivate Pten in specific mouse neuronal populations. Loss of Pten resulted in progressive macrocephaly and
seizures
. Neurons lacking Pten expressed high levels of phosphorylated Akt and showed a progressive increase in soma size without evidence of abnormal proliferation. Cerebellar abnormalities closely resembled the histopathology of human Lhermitte-Duclos disease. These results indicate that Pten regulates neuronal size in vivo in a cell-autonomous manner and provide new insights into the etiology of Lhermitte-Duclos disease.
...
PMID:Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. 1172 27
The tumor suppressor phosphatase
PTEN
can promote apoptosis of mitotic cells by inhibiting activation of the cell survival kinase Akt.
PTEN
is essential for normal embryonic development,
PTEN
expression is associated with neuronal differentiation, and deletion of
PTEN
in the mouse brain results in
seizures
, ataxia, and other abnormalities. However, the possible roles of
PTEN
in regulating neuronal survival are not known. We provide evidence that
PTEN
sensitizes hippocampal neurons to excitotoxic death in culture and in vivo. Overexpression of wild-type
PTEN
decreased, while a dominant-negative
PTEN
increased, levels of activated Akt in cultured hippocampal neurons. Wild-type
PTEN
promoted, while dominant-negative
PTEN
prevented, apoptotic death of neurons exposed to the excitatory amino acid neurotransmitter glutamate. Hippocampal neurons of mice with reduced
PTEN
levels were more resistant to
seizure
-induced death compared to wild-type littermates. These findings demonstrate a cell death function of
PTEN
in hippocampal neurons and identify
PTEN
as a potential therapeutic target for neurodegenerative disorders that involve excitotoxicity and apoptosis. The ability of
PTEN
to modify neuronal sensitivity to glutamate also suggests possible roles for
PTEN
in regulating developmental and synaptic plasticity.
...
PMID:PTEN regulates Akt kinase activity in hippocampal neurons and increases their sensitivity to glutamate and apoptosis. 1262 4
The mechanisms that regulate mammalian cell size during development and homeostatic maintenance are poorly understood. The tumor suppressor Pten is required for correct maintenance of mammalian neuronal soma size. Selective inactivation of Pten in postnatal granule neurons of the cerebellum and dentate gyrus in mouse causes cell-autonomous hypertrophy as well as more complex phenotypes, including progressive macrocephaly,
seizures
, and premature death. To determine the contribution of mTor signaling to Pten-mediated growth regulation in the mammalian nervous system, we treated Pten conditional knockout mice with CCI-779, a specific mTor inhibitor. mTor inhibition decreased the
seizure
frequency and death rate in Pten mutant mice, prevented the increase in Pten-deficient neuronal soma size in young mice, and reversed neuronal soma enlargement in adult mice. mTor inhibition did not decrease the size of wild-type adult neurons. Thus, mTor is required for neuronal hypertrophy downstream of Pten deficiency, but is not required for maintenance of normal neuronal soma size. mTOR inhibitors may be useful therapeutic agents for diseases in brain resulting from
PTEN
deficiency such as Lhermitte-Duclos disease or glioblastoma multiforme.
...
PMID:mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. 1453 28
The tumor suppressor
PTEN
(phosphatase and tensin homolog) plays a critical role in the development and maintenance of the mammalian nervous system. Effects of inherited mutation of
PTEN
are highly variable and include macrocephaly, Lhermitte-Duclos disease (LDD) caused by a hamartomatous enlargement of the cerebellum, ataxia,
seizures
and autism, in addition to cancer predisposition. In the mouse, selective inactivation of Pten in post-mitotic granule neurons of the cerebellum and dentate gyrus showed that Pten was required for proper regulation of neuronal nuclear and soma size. Hypertrophy of Pten-deficient neurons required the activity of the serine-threonine kinase mTor. mTor is a master regulator of cell and organ growth which can trigger a cascade of downstream signaling pathways involving, in part, components of the translational machinery, including S6k1 and its substrate the ribosomal protein S6. Deletion of S6k1 in mice results in decreased size. Therefore, to determine the relative contribution of S6k1 to Pten-deficient neuronal hypertrophy in vivo, we crossed Pten brain-conditional knockouts with S6k1 null mice. Double mutant mice show no reversion or improvement in their Pten-related size and neurological defects including enlarged cerebella and dentate gyri with increased size of neuronal nuclei and somata, ataxia, and premature death. The hypertrophic Pten/S6k1-deficient neurons contained high levels of phosphorylated S6, similar to Pten-deficient neurons, suggesting that the mTor/S6k/S6 branch of the pathway was still active. Thus, we conclude that S6k1 is not required to cause hypertrophy of Pten-deficient neurons. This study reveals a cell type-dependent role for S6k1 in PI3K-dependent hypertrophy.
...
PMID:S6k1 is not required for Pten-deficient neuronal hypertrophy. 1677 79
PTEN
(phosphatase and tensin homologue deleted on chromosome 10) is a tumor suppressor that can inhibit proliferation and migration and controls apoptosis in a number of cell types, mainly through inhibition of the phosphoinositide 3-kinase (PI3K) signaling pathway. Patients carrying inactivating mutations of
PTEN
show a prevalence to develop tumors that can coincide with neurological defects such as mental retardation, ataxia and
seizures
. A number of in vitro and in vivo studies were instrumental in uncovering a direct correlation between deregulated PI3K/
PTEN
signaling and changes in neuronal morphogenesis, which is likely to have profound bearings upon the pathogenesis of neurological symptoms. This review outlines recent work on the function of
PTEN
during vertebrate brain development and the current understanding of the signaling pathways downstream of
PTEN
that control neuronal connectivity in the brain.
...
PMID:Function of PTEN during the formation and maintenance of neuronal circuits in the brain. 1807 55
PTEN
(phosphatase and tensin homolog deleted on chromosome ten) is a lipid phosphatase that counteracts the function of phosphatidylinositol-3 kinase (PI3K). Loss of function of
PTEN
results in constitutive activation of AKT and downstream effectors and correlates with many human cancers, as well as various brain disorders, including macrocephaly,
seizures
, Lhermitte-Duclos disease, and autism. We previously generated a conditional Pten knock-out mouse line with Pten loss in limited postmitotic neurons in the cortex and hippocampus. Pten-null neurons developed neuronal hypertrophy and loss of neuronal polarity. The mutant mice exhibited macrocephaly and behavioral abnormalities reminiscent of certain features of human autism. Here, we report that rapamycin, a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1), can prevent and reverse neuronal hypertrophy, resulting in the amelioration of a subset of
PTEN
-associated abnormal behaviors, providing evidence that the mTORC1 pathway downstream of
PTEN
is critical for this complex phenotype.
...
PMID:Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. 1921 84
Inhibition of mTOR by rapamycin has been shown to suppress
seizures
in TSC/
PTEN
genetic models. Rapamycin, when applied immediately before or after a neurological insult, also prevents the development of spontaneous recurrent
seizures
(epileptogenesis) in an acquired model. In the present study, we examined the mTOR pathway in rats that had already developed chronic spontaneous
seizures
in a pilocarpine model. We found that mTOR is aberrantly activated in brain tissues from rats with chronic
seizures
. Furthermore, inhibition of mTOR by rapamycin treatment significantly reduces
seizure
activity. Finally, mTOR inhibition also significantly suppresses mossy fiber sprouting. Our findings suggest the possibility for a much broader window for intervention for some acquired epilepsies by targeting the mTOR pathway.
...
PMID:Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. 2056 81
Proneurotrophins and mature neurotrophins activate different signaling pathways with distinct effects on their target cells: proneurotrophins can induce apoptotic signaling via p75(NTR), whereas mature neurotrophins activate Trk receptors to influence survival and differentiation. Here, we demonstrate that the
PTEN
(phosphatase and tensin homolog deleted on chromosome 10) phosphatase represents a novel switch between the survival and apoptotic signaling pathways in rat CNS neurons. Simultaneous activation of p75(NTR) by proNGF and TrkB signaling by BDNF elicited apoptosis despite TrkB phosphorylation. Apoptosis induced by p75(NTR) required suppression of TrkB-induced phosphoinositide-3 kinase signaling, mediated by induction of
PTEN
, for apoptosis to proceed. Inhibition of
PTEN
restored the ability of BDNF to phosphorylate Akt and protect cultured basal forebrain neurons from proNGF-induced death. In vivo, inhibition or knockdown of
PTEN
after pilocarpine-induced
seizures
protected CNS neurons from p75(NTR)-mediated death, demonstrating that
PTEN
is a crucial factor mediating the balance between p75(NTR)-induced apoptotic signaling and Trk-mediated survival signaling in brain neurons.
...
PMID:ProNGF induces PTEN via p75NTR to suppress Trk-mediated survival signaling in brain neurons. 2108 16
Simple and complex forms of dysembryoplastic neuroepithelial tumors (DNTs) are readily recognizable but forms with diffuse growth pattern, and hybrid tumors, that is, mixed DNT and ganglioglioma (DNT/GG), are more contentious entities. Rare DNTs have shown aggressive behavior. We reviewed cortical growth patterns, immunophenotype (including CD34, nestin and calbindin), genetic profile, and outcome in 101 DNT in adults. Simple (n = 18), complex (n = 31), diffuse (n = 35) DNT, and mixed DNT/GG (n = 17) showed no difference in age of onset, associated
seizure
type, or outcome (67.5% free from
seizure
; mean follow-up, 6 years). CD34 was seen in 61%, calbindin in 57%, and nestin in 86% of all DNT types; these markers were less common in simple DNT. Peritumoral cortical changes (Layer I hypercellularity [61%], satellite nodules [51.6%]) were frequent, but dyslamination (cortical dysplasia) was not identified. Molecular genetic abnormalities identified in 17 cases were IDH1 mutation (n = 3), 1p/19q loss (n = 10), isolated loss 9q (n = 2), and
PTEN
loss (n = 3), which were not associated with tumor type or location, higher cell proliferation, or distinguishing clinical features (mean age of epilepsy onset, 9 years; age at surgery = 31 years; 69% free from
seizure
); none had progression on magnetic resonance imaging (mean follow-up, 6 years). No single feature was predictive of
seizure
-free outcome, but there was a trend for better outcome in CD34-positive tumors (p = 0.07). One case has shown transformation to a higher grade. This study supports the existence of a range of subtypes of DNT some with overlapping features with ganglioglioma; molecular genetic abnormalities were not predictive of atypical behavior.
...
PMID:One hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literature. 2193 11
1
2
3
Next >>